Table II.
MGMT, n (%) | |||
---|---|---|---|
|
|||
Variables | Positive | Negative | P-value |
TNM stage | |||
I | 172 (68) | 82 (32) | 0.09 |
II | 195 (60) | 131 (40) | |
III | 31 (56) | 24 (44) | |
Node status | |||
Negative | 264 (66) | 136 (34) | 0.02 |
Positive | 134 (57) | 101 (43) | |
Estrogen receptor | |||
Negative | 49 (40) | 73 (60) | 0.001 |
Positive | 349 (68) | 164 (32) | |
Progesterone receptor | |||
Negative | 76 (47) | 86 (53) | 0.001 |
Positive | 322 (68) | 151 (32) | |
HER2 | |||
Negative | 320 (65) | 173 (35) | 0.03 |
Positive | 78 (55) | 64 (45) | |
CK 5/6 | |||
Negative | 372 (63) | 222 (37) | 0.87 |
Positive | 27 (66) | 14 (34) | |
HER1 | |||
Negative | 371 (65) | 203 (35) | 0.01 |
Positive | 28 (46) | 33 (54) | |
Subtype | |||
Luminal A | 291 (68) | 134 (32) | 0.001 |
Luminal B | 64 (67) | 31 (33) | |
HER2+/ER− | 14 (30) | 33 (70) | |
Basal-like | 22 (46) | 26 (54) | |
Unclassified | 7 (35) | 13 (65) |
MGMT, O6-methylguanine-DNA methyltransferase; TNM, tumor-node-metastasis; HER1, human epidermal growth factor receptor-1; ER, estrogen receptor; CK, cytokeratin.